Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952559 | 1.00 | CHRM4 (0.38) | CHRM4CYP17A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20609193 | 1.00 | CHRM4 (0.38) | CHRM4CYP17A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20609194 | 1.00 | CHRM4 (0.38) | CHRM4CYP17A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20031740 | 1.00 | CHRM4 (0.38) | CHRM4CYP17A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20159656 | 0.92 | CHRNA3 (0.39) | CHRM4CYP17A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL18970981 | 0.79 | PSEN1 (0.46) | CHRM4CYP17A1LOXLOXL2 | |
| SCHEMBL21356458 | 0.79 | PSEN1 (0.46) | CHRM4CYP17A1LOXLOXL2 | |
| SCHEMBL18952617 | 0.79 | PSEN1 (0.46) | CHRM4CYP17A1LOXLOXL2 | |
| SCHEMBL21108536 | 0.79 | PSEN1 (0.46) | CHRM4CYP17A1LOXLOXL2 | |
| SCHEMBL18952615 | 0.79 | PSEN1 (0.46) | CHRM4CYP17A1LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3519418-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-12-08 | — | — | EP | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-109790181-B | Bridged piperidine derivatives | 豪夫迈·罗氏有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10899766-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
| WO-2017097728-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | CHRM4 4265/4885CYP17A1 2434/4885CHRNB2 662/4885 |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HTR2A, APP, PTGDR | CHRM4 1977/4885CYP17A1 3159/4885CHRNB2 434/4885 |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | PSEN1, APP, PRNP | CHRM4 2106/4885CYP17A1 3524/4885CHRNB2 932/4885 |
| US-10899766-B2 | Bridged piperidine derivatives | PSEN1, APP, PRNP | CHRM4 2106/4885CYP17A1 3524/4885CHRNB2 932/4885 |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CHRM4 2582/4885CYP17A1 3273/4885CHRNB2 666/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | CHRM4 2582/4885CYP17A1 3273/4885CHRNB2 666/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CHRM4 2582/4885CYP17A1 3273/4885CHRNB2 666/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | CHRM4 3836/4885CYP17A1 2274/4885CHRNB2 705/4885 |
| US-10875854-B2 | Triazolopyridines | HTR2A, APP, PTGDR | CHRM4 1977/4885CYP17A1 3159/4885CHRNB2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.